Verve Therapeutics (VERV) Stock Forecast, Price Target & Predictions
VERV Stock Forecast
Verve Therapeutics stock forecast is as follows: an average price target of $21.50 (represents a 290.91% upside from VERV’s last price of $5.50) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
VERV Price Target
The average price target for Verve Therapeutics (VERV) is $21.50 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $13.00. This represents a potential 290.91% upside from VERV's last price of $5.50.
VERV Analyst Ratings
According to 8 Wall Street analysts, Verve Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VERV stock is 0 'Strong Buy' (0.00%), 5 'Buy' (62.50%), 2 'Hold' (25.00%), 1 'Sell' (12.50%), and 0 'Strong Sell' (0.00%).
Verve Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 03, 2024 | Kostas Biliouris | BMO Capital | $30.00 | $8.57 | 250.06% | 445.45% |
| Dec 15, 2022 | - | Goldman Sachs | $13.00 | $22.61 | -42.50% | 136.36% |
The latest Verve Therapeutics stock forecast, released on Apr 03, 2024 by Kostas Biliouris from BMO Capital, set a price target of $30.00, which represents a 250.06% increase from the stock price at the time of the forecast ($8.57), and a 445.45% increase from VERV last price ($5.50).
Verve Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $30.00 |
| Last Closing Price | $5.50 | $5.50 | $5.50 |
| Upside/Downside | -100.00% | -100.00% | 445.45% |
In the current month, the average price target of Verve Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Verve Therapeutics's last price of $5.50. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2024 | RBC Capital | Outperform | Outperform | Hold |
| May 09, 2024 | Jefferies | Buy | Buy | Hold |
| Apr 08, 2024 | H.C. Wainwright | - | Buy | Initialise |
| Apr 03, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Apr 02, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Feb 01, 2023 | Cantor Fitzgerald | - | Neutral | Initialise |
| Dec 15, 2022 | Goldman Sachs | - | Sell | Initialise |
| Oct 06, 2022 | Credit Suisse | - | Neutral | Initialise |
| Aug 25, 2022 | Telsey Advisory | - | Buy | Upgrade |
| Feb 18, 2022 | RBC Capital | - | Outperform | Initialise |
Verve Therapeutics's last stock rating was published by RBC Capital on Aug 09, 2024. The company gave VERV a "Outperform" rating, the same as its previous rate.
Verve Therapeutics Financial Forecast
Verve Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $5.14M | $3.12M | $2.09M | $1.40M | $1.01M | $929.00K |
| Avg Forecast | $3.33M | $3.33M | $3.33M | $3.33M | $3.10M | $2.75M | $2.40M | $2.11M | $3.77M | $963.67K | $672.67K | $450.00K | $730.29K | $833.33K |
| High Forecast | $3.33M | $3.33M | $3.33M | $3.33M | $3.10M | $3.18M | $2.40M | $2.11M | $4.31M | $963.67K | $672.67K | $450.00K | $730.29K | $833.33K |
| Low Forecast | $3.33M | $3.33M | $3.33M | $3.33M | $3.10M | $2.31M | $2.40M | $2.11M | $3.23M | $963.67K | $672.67K | $450.00K | $730.29K | $833.33K |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | 1.37% | 3.23% | 3.11% | 3.12% | 1.39% | 1.11% |
Verve Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $2.11M, with a low forecast of $2.11M, and a high forecast of $2.11M. VERV's average Quarter revenue forecast represents a -59.02% decrease compared to the company's last Quarter revenue of $5.14M (Dec 23).
Verve Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | $-52.43M | $-52.33M | $-58.58M | $-58.26M | $-46.78M | $-43.86M |
| Avg Forecast | $666.67K | $666.67K | $666.67K | $666.67K | $619.23K | $549.23K | $480.29K | $421.63K | $753.02K | $192.73K | $134.53K | $90.00K | $146.06K | $166.67K |
| High Forecast | $666.67K | $666.67K | $666.67K | $666.67K | $619.23K | $635.47K | $480.29K | $421.63K | $861.68K | $192.73K | $134.53K | $90.00K | $146.06K | $166.67K |
| Low Forecast | $666.67K | $666.67K | $666.67K | $666.67K | $619.23K | $462.98K | $480.29K | $421.63K | $646.26K | $192.73K | $134.53K | $90.00K | $146.06K | $166.67K |
| Surprise % | - | - | - | - | - | - | - | - | -69.63% | -271.54% | -435.45% | -647.33% | -320.32% | -263.16% |
undefined analysts predict VERV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Verve Therapeutics's previous annual EBITDA (undefined) of $NaN.
Verve Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | $-48.35M | $-45.76M | $-53.98M | $-45.69M | $-41.09M | $-46.52M |
| Avg Forecast | $-64.50M | $-64.27M | $-62.88M | $-62.83M | $-60.20M | $-57.58M | $-57.04M | $-59.09M | $-63.52M | $-76.20M | $-77.34M | $-64.76M | $-60.69M | $-62.48M |
| High Forecast | $-64.50M | $-64.27M | $-62.88M | $-62.83M | $-60.20M | $-45.24M | $-57.04M | $-59.09M | $-55.58M | $-76.20M | $-77.34M | $-64.76M | $-60.69M | $-62.48M |
| Low Forecast | $-64.50M | $-64.27M | $-62.88M | $-62.83M | $-60.20M | $-64.98M | $-57.04M | $-59.09M | $-67.49M | $-76.20M | $-77.34M | $-64.76M | $-60.69M | $-62.48M |
| Surprise % | - | - | - | - | - | - | - | - | 0.76% | 0.60% | 0.70% | 0.71% | 0.68% | 0.74% |
Verve Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VERV's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Verve Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | $10.76M | $11.69M | $13.42M | $12.55M | $11.44M | $9.59M |
| Avg Forecast | $17.41M | $17.41M | $17.41M | $17.41M | $16.17M | $14.35M | $12.55M | $11.01M | $19.67M | $5.03M | $3.51M | $2.35M | $3.82M | $4.35M |
| High Forecast | $17.41M | $17.41M | $17.41M | $17.41M | $16.17M | $16.60M | $12.55M | $11.01M | $22.51M | $5.03M | $3.51M | $2.35M | $3.82M | $4.35M |
| Low Forecast | $17.41M | $17.41M | $17.41M | $17.41M | $16.17M | $12.09M | $12.55M | $11.01M | $16.88M | $5.03M | $3.51M | $2.35M | $3.82M | $4.35M |
| Surprise % | - | - | - | - | - | - | - | - | 0.55% | 2.32% | 3.82% | 5.34% | 3.00% | 2.20% |
Verve Therapeutics's average Quarter SG&A projection for Mar 24 is $11.01M, based on 4 Wall Street analysts, with a range of $11.01M to $11.01M. The forecast indicates a 2.31% rise compared to VERV last annual SG&A of $10.76M (Dec 23).
Verve Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | $-0.69 | $-0.72 | $-0.87 | $-0.74 | $-0.67 | $-0.81 |
| Avg Forecast | $-0.77 | $-0.76 | $-0.75 | $-0.75 | $-0.71 | $-0.68 | $-0.68 | $-0.70 | $-0.75 | $-0.90 | $-0.92 | $-0.77 | $-0.72 | $-0.74 |
| High Forecast | $-0.77 | $-0.76 | $-0.75 | $-0.75 | $-0.71 | $-0.54 | $-0.68 | $-0.70 | $-0.66 | $-0.90 | $-0.92 | $-0.77 | $-0.72 | $-0.74 |
| Low Forecast | $-0.77 | $-0.76 | $-0.75 | $-0.75 | $-0.71 | $-0.77 | $-0.68 | $-0.70 | $-0.80 | $-0.90 | $-0.92 | $-0.77 | $-0.72 | $-0.74 |
| Surprise % | - | - | - | - | - | - | - | - | 0.91% | 0.80% | 0.95% | 0.96% | 0.93% | 1.09% |
According to undefined Wall Street analysts, Verve Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VERV previous annual EPS of $NaN (undefined).
Verve Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IPSC | Century Therapeutics | $1.60 | $20.00 | 1150.00% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| NTLA | Intellia Therapeutics | $22.07 | $119.16 | 439.92% | Buy |
| EDIT | Editas Medicine | $3.95 | $17.00 | 330.38% | Buy |
| PRME | Prime Medicine | $4.09 | $17.25 | 321.76% | Buy |
| VERV | Verve Therapeutics | $5.50 | $21.50 | 290.91% | Buy |
| SANA | Sana Bio | $4.47 | $12.00 | 168.46% | Buy |
| ADPT | Adaptive Bio | $4.61 | $12.33 | 167.46% | Hold |
| RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
| BEAM | Beam Therapeutics | $26.30 | $64.20 | 144.11% | Buy |
| CRSP | CRISPR Therapeutics | $48.94 | $109.58 | 123.91% | Buy |
| CRBU | Caribou Biosciences | $2.12 | $3.00 | 41.51% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
VERV Forecast FAQ
Is Verve Therapeutics a good buy?
Yes, according to 8 Wall Street analysts, Verve Therapeutics (VERV) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 62.50% of VERV's total ratings.
What is VERV's price target?
Verve Therapeutics (VERV) average price target is $21.5 with a range of $13 to $30, implying a 290.91% from its last price of $5.5. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Verve Therapeutics stock go up soon?
According to Wall Street analysts' prediction for VERV stock, the company can go up by 290.91% (from the last price of $5.5 to the average price target of $21.5), up by 445.45% based on the highest stock price target, and up by 136.36% based on the lowest stock price target.
Can Verve Therapeutics stock reach $8?
VERV's average twelve months analyst stock price target of $21.5 supports the claim that Verve Therapeutics can reach $8 in the near future.
What are Verve Therapeutics's analysts' financial forecasts?
Verve Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $10.35M (high $10.78M, low $9.92M), average EBITDA is $2.07M (high $2.16M, low $1.98M), average net income is $-234M (high $-222M, low $-241M), average SG&A $54.08M (high $56.33M, low $51.83M), and average EPS is $-2.777 (high $-2.631, low $-2.865). VERV's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $13.33M (high $13.33M, low $13.33M), average EBITDA is $2.67M (high $2.67M, low $2.67M), average net income is $-254M (high $-254M, low $-254M), average SG&A $69.65M (high $69.65M, low $69.65M), and average EPS is $-3.021 (high $-3.021, low $-3.021).
Did the VERV's actual financial results beat the analysts' financial forecasts?
Based on Verve Therapeutics's last annual report (Dec 2023), the company's revenue was $11.76M, beating the average analysts forecast of $5.85M by 100.94%. Apple's EBITDA was $-218M, missing the average prediction of $1.17M by -18699.63%. The company's net income was $-200M, missing the average estimation of $-282M by -29.01%. Apple's SG&A was $44.48M, beating the average forecast of $30.57M by 45.52%. Lastly, the company's EPS was $-3.12, missing the average prediction of $-3.346 by -6.76%. In terms of the last quarterly report (Dec 2023), Verve Therapeutics's revenue was $5.14M, beating the average analysts' forecast of $3.77M by 36.62%. The company's EBITDA was $-52.431M, missing the average prediction of $753.02K by -7062.74%. Verve Therapeutics's net income was $-48.352M, missing the average estimation of $-63.524M by -23.88%. The company's SG&A was $10.76M, missing the average forecast of $19.67M by -45.27%. Lastly, the company's EPS was $-0.69, missing the average prediction of $-0.754 by -8.51%